Center asked India’s Comptroller General of Medicines to ensure equitable distribution of Remdesivir
New Delhi:
The Union Health Ministry has asked India’s Comptroller General of Medicines to ensure equitable distribution of the medicines Remdesivir and Tocilizumab, which have been included as ‘investigational therapies’ in national treatment protocols for COVID-19, across the country.
The aim is to ensure that their availability is not biased and does not remain confined to metropolitan areas, an official said.
The ministry sent a letter to the Comptroller General of Medicines of India (DCGI), asking him to verify how many States and Union Territories (UTs) were covered and which remained, with regard to the availability and distribution of these drugs. by the respective companies is concerned.
“I am invited to say that apart from the availability, the distribution / geographical scope of the drugs included as part of the experimental therapies in the clinical management protocols of COVID-19, namely remdesivir and tocilizumab, may also be monitored.
“This ministry may be informed of how many states and UTs have been covered and which states and UTs, if any, remain with respect to the availability and distribution of these drugs by the respective companies.” , says the letter dated July 27 said.
The ministry included the use of Remdesivir (for restricted emergency use) and the off-label application of Tocilizumab for the treatment of patients with COVID-19 in the moderate stage of the disease as “therapies. experimental ”in the updated clinical management protocol for COVID-19.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
